Early Trials of PRMT5 Inhibitors Leave Much to Be Desired, But Optimism Remains
OncLive,
Ulrik N. Lassen, MD Despite the discovery of protein arginine methyltransferase 5 (PRMT5) more than 20 years ago, interest in…
A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia
Overview of attention for article published in Blood, November 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (74th percentile)
-
Good Attention Score compared to outputs of the same age and source (71st percentile)
Readers on
- mendeley
- 26 Mendeley